- Men respond to GLP-1 medications with similar weight-loss percentages as women in pivotal trials, with somewhat higher absolute pounds lost due to higher average starting weights
- Tirzepatide produces greater average weight loss than semaglutide in men (~20–22.5% vs. ~15–17%), mirroring the cross-population pattern
- Lean-mass preservation matters more for men, who typically carry more baseline muscle mass — protecting it during weight loss is critical for long-term metabolic health
- Testosterone can transiently dip during rapid weight loss in obese men (an adaptive response), though long-term outcomes typically improve as obesity decreases
Understanding GLP-1 Options for Men in 2026
GLP-1 receptor agonists work effectively in men, and the clinical evidence base for both semaglutide and tirzepatide includes substantial male representation across the major trials. Whether you're considering semaglutide or tirzepatide, understanding how these medications perform specifically in men — and the male-specific considerations around muscle preservation and hormonal effects — helps you make a more informed treatment decision.
Weight Loss Results in Men: Semaglutide vs. Tirzepatide
Both semaglutide and tirzepatide produce substantial weight loss in men, with overall percentage results broadly similar to those seen in women across the major clinical trials. Tirzepatide produces greater mean weight loss than semaglutide in men — approximately 20–22.5% of body weight compared to approximately 15–17% for semaglutide — mirroring the same pattern observed across the broader trial populations.
One notable difference: because men on average start treatment at a higher absolute body weight than women, the same percentage of weight loss translates into a larger number of pounds lost. A man starting at 250 pounds who achieves 20% weight loss on tirzepatide loses approximately 50 pounds, compared to a woman starting at 200 pounds losing approximately 40 pounds at the same percentage.
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Average weight loss (% body weight) | 15–17% | 20–22.5% |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Compounded cost (Luma Health) | $90/month | $165/month |
| Brand-name retail cost | ~$900–$1,350/month | ~$1,000–$1,200/month |
Why Lean Mass Preservation Matters More for Men
Men typically carry more baseline muscle mass than women, which makes lean-mass preservation a particularly important consideration during GLP-1 treatment. Weight lost on GLP-1 therapy isn't exclusively fat — without intervention, a meaningful portion can come from lean tissue, including muscle. Because men generally have more muscle mass to begin with, the absolute amount of lean tissue at risk during rapid weight loss is correspondingly higher, making proactive preservation strategies especially relevant.
Protecting muscle mass during treatment isn't just about appearance — muscle tissue is metabolically active and plays a meaningful role in long-term weight maintenance, insulin sensitivity, and functional strength as you age. Losing significant muscle alongside fat can undermine some of the metabolic benefits of the weight loss itself.
Evidence-Based Strategies for Preserving Muscle
Resistance Training
2–3 sessions per week focused on compound movements (squats, deadlifts, presses, rows) provides the mechanical stimulus needed to preserve and even build muscle during a caloric deficit.
Protein Intake
Approximately 0.7–1.0 grams of protein per pound of body weight daily, individualized with your provider, supports muscle protein synthesis even while in a sustained caloric deficit from reduced appetite.
For more detailed exercise guidance during GLP-1 treatment, see our best exercise for GLP-1 patients guide.
Testosterone and GLP-1 Weight Loss
Testosterone is a frequent topic of concern for men starting GLP-1 therapy, and the relationship between weight loss and testosterone levels is genuinely nuanced. In obese men, testosterone can transiently dip during periods of rapid weight loss — this appears to be part of the body's adaptive response to significant caloric and metabolic change, rather than a sign of harm.
Importantly, the longer-term picture is generally favorable. Obesity itself is independently associated with lower testosterone levels through several mechanisms, including increased aromatization of testosterone to estrogen in adipose tissue and obesity-related insulin resistance. As body weight and fat mass decrease with successful GLP-1 treatment, testosterone levels in most men tend to improve over time compared to their pre-treatment baseline, even if there's a temporary dip during the most rapid phase of weight loss.
If you have specific concerns about testosterone levels, discuss baseline and follow-up hormone testing with your provider — this is a reasonable conversation to have as part of your overall treatment plan, particularly if you have pre-existing low testosterone or related symptoms.
Compounded vs. Brand-Name Cost Comparison
Brand-name medications like Wegovy, Ozempic, Mounjaro, and Zepbound have proven clinical effectiveness but carry retail prices of approximately $900 to $1,500 per month without insurance. Compounded alternatives containing the same active ingredients — semaglutide and tirzepatide — are available through telehealth providers like Luma Health starting at $90 to $165 per month, making treatment accessible to far more patients regardless of insurance status.
Compounded GLP-1 medications contain the same active ingredients as their brand-name counterparts. Compounded semaglutide is pharmacologically identical to the semaglutide in Wegovy and Ozempic, while compounded tirzepatide matches the tirzepatide in Mounjaro and Zepbound. The clinical mechanism, expected outcomes, and side effect profile are the same — the differences are in manufacturing source, delivery device, and price.
Can I Switch from Brand-Name to Compounded?
Yes. Switching from a brand-name to compounded GLP-1 medication is straightforward. Since the active ingredients are identical, your provider simply prescribes the equivalent compounded dose. There's no transition period, washout, or need to restart dose titration — you continue at your current dose with the compounded version at your next scheduled injection. Many patients switch specifically to reduce costs without any change in treatment efficacy.
💡 The bottom line for men: Both semaglutide and tirzepatide are effective, well-studied options. Tirzepatide tends to produce greater average weight loss, but the right choice for you depends on cost, side effect tolerance, and your specific health profile. Whichever medication you choose, prioritizing resistance training and adequate protein intake throughout treatment is the evidence-based way to protect the muscle mass you start with.
Sources & References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). NEJM. 2021;384:989–1002.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). NEJM. 2022;387:205–216.
- FDA guidance on drug compounding regulations. fda.gov/drugs/human-drug-compounding.
- NIDDK overview of prescription weight loss medications. niddk.nih.gov.
Frequently Asked Questions
Both semaglutide and tirzepatide work effectively in men, with similar weight-loss percentages as in women but somewhat higher absolute pounds lost due to higher average starting weights. Tirzepatide produces greater mean weight loss than semaglutide in men (~20–22.5% vs. ~15–17%), mirroring the broader population pattern. The right choice depends on your individual response, cost considerations, and side effect tolerance.
Weight lost on GLP-1 therapy can include some lean mass alongside fat, and this is a particular consideration for men given their typically higher baseline muscle mass. Resistance training (2–3 sessions/week, compound movements) and adequate protein intake (approximately 0.7–1.0g per pound of body weight, individualized with your provider) are the evidence-based interventions for minimizing muscle loss during treatment.
Testosterone can transiently dip during periods of rapid weight loss in obese men, an adaptive response rather than a direct medication side effect. Since obesity itself is independently associated with lower testosterone, most men see testosterone levels improve over their pre-treatment baseline as weight loss progresses, even with a temporary dip during the most rapid phase. Discuss baseline and follow-up testing with your provider if you have specific concerns.
Patients choosing compounded GLP-1 medications over brand-name options typically save 75–90% — Luma Health's compounded semaglutide ($90/month) and tirzepatide ($165/month) compare to $900–$1,500/month for brand-name equivalents. Over a year, that's a difference of roughly $9,700–$15,500 for the same general category of active ingredient.
Yes. Since the active ingredients are identical, your provider prescribes the equivalent compounded dose with no washout period or restart of dose titration. You continue at your current dose with the compounded version at your next scheduled injection.
Compounded GLP-1 medications from accredited pharmacies are generally considered safe, with the active ingredients carrying the same safety profile as brand-name versions. Quality depends on the compounding pharmacy — Luma Health uses VialsRX, a licensed 503A sterile compounding pharmacy that conducts potency and sterility testing.